Oncolytics Q4 Year End 2019 Conference Call Recap

Data presented by academic collaborators from Cancer Research UK at the International Oncolytic Viral Conference demonstrate synergistic activity between pelareorep and CDK4/6

Interested in a recap of what we’ve been up to since the beginning of 2019? Last week, CEO Matt Coffey and CFO Kirk Look, provided an update on the significant progress during this period during our Q4 Year End 2019 earnings call. They discussed everything from the discovery of our biomarker, to clinical programs to potential new indications for pelareorep.  As well as the strongest financial position for Oncolytics in many years.  The Oncolytics Team is now focused on execution and delivering on a large number of catalysts in 2020 and 2021.   

Below, we’ve captured an excerpt from the call that highlights one of the more exciting advancements: potential synergies with the CDK4/6 drug class. 

“The preclinical data demonstrated synergistic activity between pelareorep and Pfizer’s CDK4/6 inhibitor, Ibrance, which is currently used as the first line treatments for metastatic HR+ / HER2- breast cancer. The preliminary data suggest that pelareorep synergizes with CDK4/6 inhibitors by blocking cellular signaling pathways releasing more double-stranded RNA into the tumor cell and triggering immunogenic cell death resulting in another effective way to make a cold tumor very, very hot.

Between IND 213 and BRACELET-1 we are currently targeting the second line metastatic setting estimated to be approximately $2 billion. The potential to work in combination with CDK4/6 drugs in the first line metastatic breast cancer setting can than double this opportunity.

The AWARE-1 data and preclinical data with CDK4/6 drugs also indicates that pelareorep creates significant viral replication in early stage primary breast cancer, suggesting role for pelareorep in this treatment setting as well. A particular interest here is pelareorep’s demonstrated memory or vaccination effect, raising the hope that these early stage primary disease patients are less likely to experience disease recurrence. This suggests that pelareorep has the potential to grow the opportunity for CDK4/6 drugs already on pace to sell well over $6 billion in 2020 in primary disease, as well and become an integral component across the breast cancer treatment spectrum.

The impact of pelareorep in breast cancer from early to late stage disease represents a massive multibillion-dollar opportunity. Again, no study has been defined and the CDK4/6 combinations will not distract us from our focus on the Phase 3 in metastatic breast cancer, but this could represent a significant opportunity for any pharma with a CDK4/6 inhibitor or drug candidate in an opportunity our team is definitely looking at.”

For more information you can listen to the full call or read the press release.